San Francisco—NVIDIA will associate with Illumina to apply genomic technologies and AI to analyze and interpret multi-image data in the discovery of drugs, clinical research and human health, companies said in a collaboration of technology leaders announced at the start of 43RD Annual JP Morgan health conference.
Illumina will offer its Draghen analysis software on the accelerated IT platforms of Nvidia and will make the Bionemo tools of Nvidia available on the Illumina Connected Analytics (ICA) platform of the new generation giant. By integrating their technologies, companies aim to extend the scope of the Multi-Imical and Illumina Multi-Illuma analysis around the world where users access the IT platform of Nvidia.
“Nvidia was very successful in the construction of GPU as an acceleration platform, and they have a wide distribution of this asset. They have gpu everywhere led by the AI demand that has increased. We work together to make sure that we can also execute GPUS, Rami Mehio, Illumina, the world software chief and information, your tad General advantage.
This work, said Mehio, has been underway for a year and is very far, but will take an additional time to finish.
“Our code is large enough, and to make it essentially effective on GPU, takes time,” said Mehio. “The two teams, Nvidia and us, worked there together. We have prototypes that work today, but they are not yet production quality. We always add features and deleting the bugs. ”
“I would expect that we certainly have something before the end of this available year,” added Mehio.
Integration from Nvidia to Dragen and Illuma Connected Analytics Help Nvidia at a time when he works with several unknown countries when they establish national Sovereign AI strategies.
“Really unique opportunity”
“They want to protect their Population Data, but they also want to create the conditions that will enable them to have a world-class health system, all at the same time. So, we have a really unique opportunity by Bringing Dragen in the illumina platform on our gpus,” Kimberly Powell, NVIDIA Healthcare and Life Sciences, Told Gen Edge. “”We will have the ability to really bring all these astonishing genomic capacities in these sovereign AI efforts and allow them to have cutting -edge genomic capacities in these countries. »»
Nvidia and Ellumina also agreed to collaborate in the progression of the analysis of multi-ordinary data using the Illumina connected analysis, in addition to developing new models of biology foundation, with plans to incorporate the image processing of Nvidia and unique tertiary analysis tools on the Connected Illumina software.
Companies have declared that their researchers will also work to integrate via connected analyzes illuminated a range of Nvidia technologies ranging from NVIDIA RAPIDS ™ Accelerated data science software included in the NVIDIA AI ENTERPRISE software platform; At Nvidia Bionemo ™ Generative AI platform for the discovery of drugs, including generative AI models and fine adjustment capacities for proprietary data sets; and the NVIDIA MONAI Framework for space Cell Imaging Workflows.
“By bringing them to the connected analysis platform (illumina), we will essentially broaden and considerably develop the genomic ecosystem in places such as the research community, in places such as the discovery of drugs, in the hope that each clinic of the planet, because we are moving from the reading of the human genome in the type of perspectives that we can bring together this human genome” Powell.
“There is a deep desire by more and more parts of the industry who wish to discover more on biology, on the disease, to use these tools in order to find new drugs or to offer better treatment strategies,” said Powell. “The challenge is that the whole human genome is not yet readable by man. It must be readable in the machine. Then you want to continue to obtain information from this data. We are really when we have to start applying automatic learning and artificial intelligence much more seriously.”
Visit Jensen Huang
Mehio d’Illumina said the collaboration started exactly a year ago at the JP Morgan Healthcare conference last year, when he joined the new CEO of Illumina, Jacob Thaysen, PHD, to meet the founder and chief executive officer of Nvidia, Jensen Huang at his home.
“This launched our initial work on the portage of Dragen, but also taking into account these organic-foundational models that we want to explore together, which really hold the promise of the future,” recalls Mehio.
Companies continued two tracks when they started to collaborate. One was knowing how to take advantage of the availability of GPUs with Dragen. “And the second part we have discussed is essentially how Nvidia and the world are in the middle of a revolution in AI, and genomics is something that would benefit,” said Mehio.
“Our first foray into this field essentially consists in introducing Nvidia’s and calculation capacity in our data platform, Illumina Connected Analytics and complete it with our own AI efforts and analysis that we do to drive this new space of fundamental models for biology and so on,” summed up Mehio. “So, two pieces in collaboration. We have progressed far the first, and we are in the initial stages of the second.”
Multimodal AI models that should result from business efforts can reveal information and rationalize processes to increase the capacities of human experts, Ilumina CEO, informal “cat” hosted by Nvidia CEO on Monday evening at the Fairmont San Francisco conference, told Huang.
“Combining other information, other modalities, other” ommics “,” observed Thaysen, “will give us a much deeper overview of biology. But while DNA was very difficult, when you combine all the ommics, it becomes exponentially more difficult.
Companies said their partnership was intended to extend the global genomics market further – projected at 37.94 billion dollars last year by priority research in a report published on December 31 and help allow breakthroughs in the identification of targets, the development of drugs in clinical phases and the discovery of biomarkers.
Push
“There are many reasons to continue to push the capacity to reduce the cost and increase speed, to introduce new approaches such as artificial intelligence, and to really extend the market,” said Powell.
Approach the 43RD On Monday, Powell offered additional details on collaboration and potential customers for combined offers.
“We are going to work together to create new applications in the analyzes connected to Illumina, by providing genomic foundation models, by providing unicealic applications which are essentially in real time on a very, very large scale and expanding genomic accessibility and usefulness in new markets such as the discovery of drugs,” said Powell.
“We still have so much to discover the fundamental elements of biology. It is in the incredible data that he does generate, and now we will work together to create these tools, create these capacities and extend the genomic market in the next generation, in the generation of general AI, and all the way to make more accessible to the research community, the Biopharma community and Bioch Powell added.
Steven Barnard, PHD, CTO d’Ellumina, said General advantage That NVIDIA collaboration absorbs the three -pilot approach to its business in the future of its technological strategy. The pillar one involves continuing to offer instrumentation and peak sequencing. Pillar two, expanding the content offers of Illumina in multi-orders, as articulated by the CEO Jacob Thaysen, PHD, in a recent Generation interview.
Pillar three, Barnard elaborated, “is the ability to be essentially the de facto insight and interpretation for all this biological data”.
“Besides the software above the hardware, having the best tools, having the best technology to support this third pillar is extremely important,” added Barnard, who joined Illumina in 1998 as the first scientist and fourth employee of the company.
Iqvia, Mayo Clinic and Arc Institute
The illumina collaboration was one of the four partnerships announced today by Nvidia. The other three are:
- Iqvia—The global supplier of clinical research services, commercial information and health intelligence for life sciences and health care companies plans to use the NVIDIA AI foundry service to build personalized foundation models on its more than 64 information petacts, associated with its deep expertise in the field. IQVIA also develops agental AI solutions – at the NVIDIA NIM ™ microservice level and NVIDIA plans – designed to accelerate research, clinical development and access to new treatments.
- Mayo clinic– The largest integrated practice of medical group integrated into the world has joined Nvidia to say that they “massively” accelerate the development of new generation pathology foundation models, as “angular stone” for future AI applications in the discovery of drugs, as well as personalized diagnoses and treatments. Mayo Clinic plans to deploy newly available NVIDIA DGX ™ B200 systems based on NVIDIA Blackwell architecture, offering 1.4 TB of GPU memory per system and the Monai Healthcare imaging platform from NVIDIA.
- Arc Institute—The research organization of research in biology / machine-learning based on CA, CA, will associate with Nvidia to develop and share AI models and tools intended to advance biomedical discovery. Arc researchers and NVIDIA engineers will increase foundation models for biology designed to generalize between DNA, RNA and protein medication methods, as well as prior applications for the discovery of drugs and synthetic biology through the scales of complexity, diseases and research on evolution. NVIDIA said that he had provided Arc an expertise in the development of large-scale models as well as on the Nvidia Bionemo platform operating on NVIDIA DGX ™ Cloud, designed for optimized and easy-to-use training; and Nvidia Nim Microservices and Blueprints.